Ranbaxy Rules Out "At-Risk" Lipitor Launch: Report

Law360, New York (January 26, 2005, 12:00 AM EST) -- Indian generic maker Ranbaxy Laboratories Ltd. won’t launch a generic version of Pfizer Inc.’s best-selling anti-cholesterol drug Lipitor “at risk” if it wins its patent challenge at the district-court level, according to a published report.

Chief Executive Brian Tempest told Reuters that he would await the outcome of any appeal before introducing a generic version of the cholesterol-lowering medicine in the United States.

“We wouldn't launch at risk. We are a conservative company. We will wait until the appeal at the federal level,” Tempest told the...
To view the full article, register now.